ClinicalTrials.gg
TerminatedNCT01261624Updated Apr 16, 2014Results posted

Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis

A Phase 2 interventional study of Givinostat in Polyarticular Course Juvenile Idiopathic Arthritis, sponsored by Italfarmaco. Terminated at 13 sites in 7 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-04-16.

Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment

Why this study was terminated
The primary reason for the decision to discontinue the study is lack of enrolment; this decision is not related to any tolerability concerns with Givinostat

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Arthritis, Juvenile with a site in Italy — 20 open to participants now, 24 under way, 11 of them phase 3. Arthritis, Juvenile · Italy.

Enrollment
42nd of 43
16 · median 90
Started
2010
the only one that year
Phase 2
5 of 56
2 open now
Registered
12th of 56
by date

Among the 56 studies in Arthritis, Juvenile with a site in Italy, this one is the 42nd largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2010, is one of 5 in phase 2, and was the 12th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 56 studies in Arthritis, Juvenile with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Arthritis, Juvenile with a site in Italy, or all of them as a file.
02

Study summary

The present study has been designed in order to evaluate the efficacy and safety of two doses of Givinostat in subjects with polyarticular course JIA

Givinostat ready-to-use suspension especially intended for paediatric administration, will be administered orally at different daily doses.

Patients with an established diagnosis of one of the following JIA forms (Polyarticular JIA rheumatoid factor positive or negative, Oligoarticular extended JIA, Systemic JIA without active systemic features) will be enrolled.

The treatment regimen will remain unchanged for 12 weeks and the clinical response will by assessed by applying the ACR Pediatric response criteria. Patients achieving at least an ACR Pediatric 30 response will continue receiving the assigned dose for 12 further weeks.

After the end of study (week 24) responder patients will be allowed to extend the treatment until they maintain a clinical benefit.

Read the detailed description

Non-clinical data on Givinostat, support a potent anti-inflammatory mechanism of action which can potentially slow the arthritic destructive process. This rationale seems to be confirmed by the preliminary evidences collected in a previous Phase II clinical trial conducted in children and young adults with systemic JIA.

The present protocol is aimed at collecting new information on safety and efficacy of two doses of Givinostat for the treatment of JIA.

03

Conditions studied

  • Polyarticular Course Juvenile Idiopathic Arthritis

Browse trials for

Keywords

  • poly JIA
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients of both genders, aged 2 to 17 years, with established diagnosis of polyarticular course Juvenile Idiopathic Arthritis (see before for specific subtypes) according to ILAR (International League Against Rheumatism) criteria (Petty RE et al., 2004) for at least six months before the study entry
  • age at polyarticular JIA diagnosis \< 16 years
  • active disease for at least 6 months prior to enrolment as defined by the following criteria:
  • presence of at least 5 active joints (those with swelling or, in the absence of swelling, limited range of motion accompanied by pain/tenderness)
  • inadequate response to, or intolerance to, at least one biologic agent such as, but not limited to, etanercept, infliximab, and adalimumab.
  • maximum allowed dose 0.2 mg/kg/day or 10 mg/day (whichever is lower) of prednisone or equivalent
  • in case of concomitant methotrexate treatment, it has to be on a stable dose ≤15 mg/m2 weekly for at least 1 month before patient's enrolment
  • other disease-modifying anti-rheumatic drugs possibly previously introduced have to be discontinued for a period of at least five half-lives
  • concomitant nonsteroidal anti-inflammatory drugs, if any, on a stable dose for at least four weeks before patient's enrolment

Exclusion criteria

Exclusion Criteria:

  • patient with fever related to JIA or other systemic features of JIA during 12 months before entering the study
  • active bacterial or mycotic infection requiring antimicrobial treatment
  • episode of macrophage activation syndrome in the last 6 months
  • a baseline prolongation of /QTc interval, use of concomitant medications that prolong the QT/QTc interval or history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) (Appendix C)
  • cardiovascular disease
  • clinically significant illness i.e. any condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study
  • psychiatric illness/social situations that would limit compliance with study medication and protocol requirements
  • inherited metabolic diseases
  • presence of
  • pregnancy or lactation
  • positive blood test for
  • active EBV infection, active B and/or C hepatitis
  • count \<100x109/L
  • \<1.5x109/L
  • serum creatinine >2xULN ().
  • total serum >1.5xULN.
  • serum /ALT > 3xULN.
  • congenital heart and/or central nervous system disorders
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Givinostat 1.0 mg/kg daily

    Drug: Givinostat

  • Experimental
    Givinostat 1.5 mg/kg daily

    Drug: Givinostat

Interventions

  • 1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition

06

What researchers measure

Primary outcomes

  1. ACR Pediatric Response Level (ACRPRL) 30 After 12 Weeks of Treatment

    ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0-100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 30 of response, defined as a 30% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%

    Time frame: 12 weeks of treatment

Secondary outcomes

  1. ACR Pediatric Response Level (ACR 50, 70, 90 and 100) at Week 12

    ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0- 100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 50, 70, 90 and 100 of response, defined as a 50%, 70%, 90% and 100% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%

    Time frame: at week12

07

Results

Posted Apr 16, 2014

Participant flow

Recruitment period: October 2010 - December 2011. The study was conducted by nine Investigators in five countries across Europe; three Investigators in Italy, two Investigators each in Romania and Serbia, and one Investigator each in Czech Republic and Slovenia

Week 0 to Week 12
Participant flow — Week 0 to Week 12
MilestoneLow Dose Treatment Cohort (LDTC): 0.50 mg/kg Twice Daily (BID)High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID
Started106
Completed93
Not completed13
Withdrew: Disease progression11
Withdrew: Insufficient response02
Week 13 to Week 24
Participant flow — Week 13 to Week 24
MilestoneLow Dose Treatment Cohort (LDTC): 0.50 mg/kg Twice Daily (BID)High Dose Treatment Cohort (HDTC): 0.75 mg/kg BID
Started111
Completed110
Not completed01
Withdrew: Insufficient response01

Outcome measures

PrimaryACR Pediatric Response Level (ACRPRL) 30 After 12 Weeks of Treatment

ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0-100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 30 of response, defined as a 30% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%

Time frame:
12 weeks of treatment
Reported as:
Number · participants
ACR Pediatric Response Level (ACRPRL) 30 After 12 Weeks of Treatment
participantsLow Dose DiscontinuedLow Dose ThroughoutSwitched DoseHigh Dose ThroughoutHigh Dose Discontinued
ACR Pediatric Response Level 3001321
No response10503
SecondaryACR Pediatric Response Level (ACR 50, 70, 90 and 100) at Week 12

ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0- 100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 50, 70, 90 and 100 of response, defined as a 50%, 70%, 90% and 100% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%

Time frame:
at week12
Reported as:
Number · participants
ACR Pediatric Response Level (ACR 50, 70, 90 and 100) at Week 12
participantsLow Dose DiscontinuedLow Dose ThroughoutSwitched DoseHigh Dose ThroughoutHigh Dose Discontinued
ACR Pediatric response Level 5001121
ACR Pediatric response Level 7001010
ACR Pediatric response Level 9000000
ACR Pediatric response Level 10000000

Adverse events

Collected over Planned treatment duration was 24 weeks overall (12 weeks + 12 weeks). The mean (SD) duration of treatment was 131.9 (55.9) days overall, with a median duration of 170 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose Discontinued—0/1 (0%)1/1 (100%)
Low Dose Throughout—0/1 (0%)1/1 (100%)
Switched Dose—0/8 (0%)8/8 (100%)
High Dose Throughout—0/2 (0%)2/2 (100%)
High Dose Discontinued—0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 48
Most frequent other events
EventLow Dose DiscontinuedLow Dose ThroughoutSwitched DoseHigh Dose ThroughoutHigh Dose Discontinued
Abdominal Pain UpperGastrointestinal disorders1/10/11/80/20/4
DiarrhoeaGastrointestinal disorders1/10/10/80/21/4
PharyngitisInfections and infestations0/11/10/80/21/4
Upper Respiratory Tract InfectionInfections and infestations1/10/10/80/20/4
Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders1/10/10/80/20/4
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders1/10/10/80/20/4
Frequent Bowel MovementsGastrointestinal disorders0/10/10/81/20/4
VomitingGastrointestinal disorders0/10/11/81/21/4
Respiratory Tract InfectionInfections and infestations0/10/11/81/20/4
HeadacheNervous system disorders0/10/11/80/22/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BIDHigh Dose Treatment Cohort (HDTC): 0.75 mg/kg BIDTotal
Mean11.7 ± 5.59.7 ± 5.710.9 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BIDHigh Dose Treatment Cohort (HDTC): 0.75 mg/kg BIDTotal
Female8614
Male202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BIDHigh Dose Treatment Cohort (HDTC): 0.75 mg/kg BIDTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White10616
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BIDHigh Dose Treatment Cohort (HDTC): 0.75 mg/kg BIDTotal
Serbia516
Czech Republic112
Slovenia112
Romania101
Italy235
Body Weight
Body Weight(kg)Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BIDHigh Dose Treatment Cohort (HDTC): 0.75 mg/kg BIDTotal
Mean37.36 ± 15.4037.92 ± 18.5937.57 ± 16.05
Height
Height(m)Low Dose Treatment Cohort (LDTC): 0.50 mg/kg BIDHigh Dose Treatment Cohort (HDTC): 0.75 mg/kg BIDTotal
Mean1.388 ± 0.2041.365 ± 0.2771.379 ± 0.225
08

Study locations

13 sites
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • 1st Faculty of Medicine and General Faculty Hospital
    Praha 2, Praha 12109, Czech Republic
  • Ospedale Meyer
    Firenze, FI 50139, Italy
  • Policlinico G. Martino
    Messina, ME 98125, Italy
  • Istituto Gaetano Pini
    Milano, MI 20122, Italy
  • Azienda Ospedaliera-Università di Padova
    Padova, PD 35128, Italy
  • Institutul pentru Ocrotirea Mamei si Copilului "Alfred Rusescu"
    Bucarest, 020395, Romania
  • Spitalul Clinic de Urgenta pentru Copii "M.S. Curie"
    Bucarest, 041451, Romania
  • Mother and Child Health Institute "Dr Vukan Cupic"
    Novi Beograd, Belgrade 11070, Serbia
  • Institute of Rheumatology Belgrade
    Belgrade, 11000, Serbia
  • University Clinical Center Nis
    Nis, 18000, Serbia
  • Children's Hospital - University Medical Centre Ljubljana
    Ljubljana, SI-1000, Slovenia
  • Hospital Ramón y Cajal
    Madrid, 28034, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Jun 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2010
First posted
Dec 16, 2010
Start
Oct 2010
Primary completionActual
Jun 2012
CompletionActual
Mar 2013
Results first posted
Apr 16, 2014
Last update
Apr 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01261624
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Dec 16, 2010
Start date
Oct 2010
Primary completion
Jun 2012
Completion
Mar 2013
Results posted
Apr 16, 2014
Last update
Apr 16, 2014

Study contacts

Francesco Zulian, MD
principal investigator · Azienda Ospedaliera-Università di Padova - Unità di Reumatologia Pediatrica

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion